Yarrow Bioscience Director Zeronda Tyler Receives Option Award

What Happened

• Zeronda Tyler, a director of Yarrow Bioscience (YARW), was granted a derivative award on 2026-07-27: an option/right to purchase 185,798 shares of common stock. The Form 4 reports the acquisition as a derivative grant (transaction code A) at $0.00; the filing does not state an immediate cash value or the option exercise price. This is an award/compensation grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-07-27; Form 4 filed: 2026-07-29 (timely filing).
• Security: Option/right to purchase 185,798 shares (reported as derivative acquisition, A).
• Price reported on Form 4: $0.00 (typical for grant entries); exercise price/value not disclosed in the filing.
• Shares owned after transaction: Not stated in the filing.
• Vesting (from footnote F1): 1/4 vests on July 27, 2027; remaining 3/4 vest in equal monthly installments over the following three years, subject to continued service.
• Other: Exhibit 24 (Power of Attorney) attached to the filing.

Context

• This was a grant of options/rights, not an exercise or sale — no shares were sold or immediately issued. Such awards are common as compensation to align executive/director incentives and only convert to vested, exercisable equity over time. The filing provides vesting terms but does not disclose the exercise price or immediate cash value.